Seres Therapeutics (MCRB) Expected to Announce Earnings on Tuesday

Seres Therapeutics (NASDAQ:MCRB) is expected to be releasing its earnings data before the market opens on Tuesday, March 4th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter.

Seres Therapeutics Stock Up 4.7 %

Shares of Seres Therapeutics stock opened at $0.76 on Friday. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53. The business’s fifty day moving average is $0.83 and its two-hundred day moving average is $0.84. The firm has a market cap of $129.64 million, a PE ratio of -3.30 and a beta of 2.11.

Wall Street Analyst Weigh In

MCRB has been the topic of several recent analyst reports. Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.08.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.